1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer

Technology appraisal guidance [TA424] Published date: 21 December 2016

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Resource impact report 21 December 2016   PDF 323.1 KB
  • Resource impact template 21 December 2016   Excel 1.02 MB

Guidance into practice

  • About the Into practice guide
  • Practical steps to improving the quality of care and services using NICE guidance
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • NICE and the public
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions
  • Privacy notice

© NICE [year]. All rights reserved. Subject to Notice of rights.